6505--Rituximab and Biosimilars

Active

Contract Opportunity

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0021 for an unrestrictive procurement for Rituximab for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BoP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract item(s) will be distributed through the VA s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation 36E79725R0021 will be electronically issued in commercial product format in accordance with FAR Part 12 on or about February 17, 2025, with a tentative closing date of March 4, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: www.sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Deb Fassl. Questions can be e-mailed to: Deborah.Fassl@va.gov.

The estimated annual requirement is as follows:

ITEM
DESCRIPTION
PKG SIZE
(ML per Vials)
TOTAL ESTIMATED ANNUAL USAGE
(Vials)
1
RITUXIMAB 10MG/ML AND BIOSIMILARS*
10
17,858
2
RITUXIMAB 10MG/ML AND BIOSIMILARS*
50
25,111

*Proposed biosimilar products must be biological products licensed by the FDA under 42 U.S.C § 262 and must meet all biosimilar criteria described in 42 U.S.C. § 262. Additionally, Biosimilars Products must be FDA approved as a biologic medication that is compared to the innovator (the original biologic) and listed as a biosimilar to the innovator in the FDA Purple Book (https://purplebooksearch.fda.gov/).

Attachments/Links